Saint-Prex, Switzerland, 1 November 2013 – Ferring Pharmaceuticals announced today that it has appointed Alex Chang to head the company’s Asia Pacific region effective 1 November 2013. Mr. Chang will report directly to Michel Pettigrew, President of the Executive Board and COO, Ferring Group. As Senior Vice President, Asia Pacific, Mr. Chang will be responsible for continued development and performance of Ferring businesses in China, Japan, South Korea, South East Asia, India, Australia, New Zealand and South Africa.
With a career spanning over 24 years in the global pharmaceutical industry, Alex Chang has held positions in Singapore, Shanghai, Beijing, Guangzhou, Taipei, Hong Kong and the United States. As Head of the Asia Cluster at Novartis since 2011, Mr. Chang led nine country operations and 2,700 employees. Prior to Novartis, he held several senior management positions for Janssen in China and Taiwan and for Bristol-Myers Squibb in China and the USA.
"We are happy to welcome Alex to the Ferring team. We are confident that his deep industry knowledge and broad regional experience will contribute to Ferring growth in the Asia-Pacific region," said Michel Pettigrew, President of the Executive Board and COO, Ferring Group.
- ENDS -
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in 55 countries and markets its products in more than 100 countries. To learn more about Ferring or its products please visit www.ferring.com.
For further information, contact:
Tel: +41 58 301 00 51
Tel: +41 58 301 00 53